DefEYE Launches as Independent Company – News & Updates
- main Topic: DefEYE, a company focused on ocular surface optimization, has announced new developments including a Biovance 3L Ocular graft and key personnel additions.
- * Biovance 3L Ocular: This is a decellularized human amniotic membrane (AM) graft designed to improve corneal epithelial defects, dry eye, and neurotrophic keratitis.It has strong tissue adherence...
Here’s a breakdown of the provided text, extracting key information:
main Topic: DefEYE, a company focused on ocular surface optimization, has announced new developments including a Biovance 3L Ocular graft and key personnel additions.
key Points:
* Biovance 3L Ocular: This is a decellularized human amniotic membrane (AM) graft designed to improve corneal epithelial defects, dry eye, and neurotrophic keratitis.It has strong tissue adherence and doesn’t require sutures or glue.
* Rob Sambursky, MD (CEO of DefEYE): Emphasized the importance of ocular surface optimization for both symptom management and surgical outcomes.
* New Personnel:
* robert Glashow: chief Financial Officer
* Rahim Hirji, RPH: Senior Vice President of Marketing
* Tyler Johnson: Vice President of Market Advancement
* Rebecca Chandler: Vice President of Strategic Accounts
* Additional Biologics: DefEYE has commercial rights to other decellularized human placenta-derived biologics with potential in eye care.
* Previous research: A previous Healio report showed that a decellularized AM basement membrane combined with eyelid pressure patching was effective in healing corneal epithelial defects.
Source: Press Release from DefEYE.
Disclosure: Rob Sambursky is the CEO of DefEYE.
Publication: Ocular Surgery News (Healio).